HomeCompareFSTX vs KMB

FSTX vs KMB: Dividend Comparison 2026

FSTX yields 28.09% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FSTX wins by $72.6K in total portfolio value
10 years
FSTX
FSTX
● Live price
28.09%
Share price
$7.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$118.5K
Annual income
$14,804.06
Full FSTX calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — FSTX vs KMB

📍 FSTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSTXKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSTX + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSTX pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSTX
Annual income on $10K today (after 15% tax)
$2,387.64/yr
After 10yr DRIP, annual income (after tax)
$12,583.45/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, FSTX beats the other by $8,153.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSTX + KMB for your $10,000?

FSTX: 50%KMB: 50%
100% KMB50/50100% FSTX
Portfolio after 10yr
$82.2K
Annual income
$10,007.69/yr
Blended yield
12.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

FSTX
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
0.7
Piotroski
3/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSTX buys
0
KMB buys
0
No recent congressional trades found for FSTX or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSTXKMB
Forward yield28.09%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$118.5K$45.9K
Annual income after 10y$14,804.06$5,211.33
Total dividends collected$78.8K$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: FSTX vs KMB ($10,000, DRIP)

YearFSTX PortfolioFSTX Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$13,509$2,808.99$11,314$613.68+$2.2KFSTX
2$18,001$3,546.41$12,865$759.19+$5.1KFSTX
3$23,678$4,416.52$14,709$943.96+$9.0KFSTX
4$30,764$5,429.21$16,919$1,180.17+$13.8KFSTX
5$39,510$6,592.67$19,588$1,484.33+$19.9KFSTX
6$50,189$7,913.03$22,838$1,879.06+$27.4KFSTX
7$63,097$9,394.15$26,832$2,395.60+$36.3KFSTX
8$78,551$11,037.47$31,788$3,077.63+$46.8KFSTX
9$96,891$12,841.93$38,000$3,986.82+$58.9KFSTX
10$118,478$14,804.06$45,872$5,211.33+$72.6KFSTX

FSTX vs KMB: Complete Analysis 2026

FSTXStock

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

Full FSTX Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this FSTX vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSTX vs SCHDFSTX vs JEPIFSTX vs OFSTX vs KOFSTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.